Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam EXBLIFEP safety profile was comparable to piperacillin-tazobactam SAINT-LOUIS, France and WEIL AM RHEIN, Germany, Feb. 25, 2020 (GLOBE NEWSWIRE) — Allecra Therapeutics today announced that its investigational product EXBLIFEP (cefepime-enmetazobactam) met the U.S. Food and Drug Administration (FDA) […]

Read more

Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) — Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant infections, today announced four upcoming presentations at the ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, taking place September 3-6 in Boston, […]

Read more